Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.

MLA

LaPensee, Kenneth, et al. “Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.” American Health & Drug Benefits, vol. 12, no. 1–Supplement 2, Feb. 2019, pp. S13–24. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=30996767&authtype=sso&custid=ns315887.

APA

LaPensee, K., Mistry, R., & Lodise, T. (2019). Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections. American Health & Drug Benefits, 12(1–Supplement 2), S13–S24.

Chicago

LaPensee, Kenneth, Rohit Mistry, and Thomas Lodise. 2019. “Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.” American Health & Drug Benefits 12 (1–Supplement 2): S13–24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=30996767&authtype=sso&custid=ns315887.